TG Therapeutics, Inc. $TGTX Stock Holdings Lifted by Invesco Ltd.

Key Points

• Invesco Ltd. increased its stake in TG Therapeutics by 30.2%, acquiring an additional 281,099 shares in the first quarter, valuing their total ownership at approximately $47.7 million.
• Multiple institutional investors, including Envestnet Asset Management and Russell Investments Group, also reported increased holdings in TG Therapeutics, accumulating to 58.58% of the company's total stock ownership.
• The company recently reported a quarterly EPS of $0.17, which fell short of analysts' expectations, while revenue grew by 92.1% year-over-year, totaling $141.15 million.

Invesco Ltd. increased its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 30.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,210,842 shares of the biopharmaceutical company's stock after buying an additional 281,099 shares during the quarter. Invesco Ltd. owned about 0.76% of TG Therapeutics worth $47,744,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Pandora Wealth Inc. bought a new position in TG Therapeutics in the 1st quarter worth approximately $3,300,000. Citigroup Inc. grew its holdings in TG Therapeutics by 0.6% in the 1st quarter. Citigroup Inc. now owns 349,104 shares of the biopharmaceutical company's stock worth $13,765,000 after buying an additional 1,927 shares in the last quarter. Deutsche Bank AG grew its holdings in TG Therapeutics by 1.1% in the 1st quarter. Deutsche Bank AG now owns 148,705 shares of the biopharmaceutical company's stock worth $5,863,000 after buying an additional 1,685 shares in the last quarter. WealthShield Partners LLC bought a new position in TG Therapeutics in the 1st quarter worth approximately $239,000. Finally, Thoroughbred Financial Services LLC bought a new position in TG Therapeutics in the 1st quarter worth approximately $324,000. 58.58% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, The Goldman Sachs Group raised TG Therapeutics to a "hold" rating and set a $37.00 price objective for the company in a report on Thursday, July 10th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $46.25.

TG Therapeutics Price Performance

TGTX traded up $0.3870 during trading on Friday, reaching $29.1570. The stock had a trading volume of 447,085 shares, compared to its average volume of 2,480,795. The firm has a market capitalization of $4.63 billion, a price-to-earnings ratio of 78.62 and a beta of 1.95. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. TG Therapeutics, Inc. has a 1-year low of $21.11 and a 1-year high of $46.48. The stock has a 50 day moving average of $34.23 and a two-hundred day moving average of $35.71.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). The firm had revenue of $141.15 million during the quarter, compared to analyst estimates of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business's revenue for the quarter was up 92.1% on a year-over-year basis. During the same quarter last year, the company earned $0.04 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Insiders Place Their Bets

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the company's stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the sale, the director directly owned 228,816 shares in the company, valued at $8,452,463.04. This represents a 4.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.64% of the stock is owned by company insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.